<DOC>
	<DOCNO>NCT01347268</DOCNO>
	<brief_summary>Ovarian hyperstimulation syndrome ( OHSS ) serious complication ovulation induction life threaten iatrogenic complication . In patient GnRH agonist protocol , withdraw GnRH agonist GnRH antagonist administration associate reduction ( E2 ) level subsequent decrease incidence severity OHSS . This work compare clinical endocrine outcome response cycle GnRH agonist withdraw cycle GnRH antagonist administration patient risk severe OHSS .</brief_summary>
	<brief_title>Comparing Coasting Withholding GnRH Agonist With GnRH Antagonist</brief_title>
	<detailed_description>Background : Elevated estradiol ( E2 ) level multiple folliculogenesis predispose development ovarian hyperstimulation syndrome ( OHSS ) . In patient GnRH agonist protocol , withdraw GnRH agonist GnRH antagonist administration associate reduction ( E2 ) level subsequent decrease incidence severity OHSS . This work compare clinical endocrine outcome response cycle GnRH agonist withdraw cycle GnRH antagonist administration patient risk severe OHSS . Purpose : To compare decreased level estradiol ( E2 ) , coast day , severity OHSS pregnancy outcome cycle GnRH agonist withdraw cycle GnRH antagonist administration patient risk severe OHSS . Methods : prospective randomize study design evaluate clinical endocrine outcome two different coast protocol . Women ( n=120 ) control ovarian hyperstimulation GnRH agonist protocol risk OHSS ( ≧20 follicle &gt; 12 mm development E2 &gt; 4000 pg/ml ) randomize two group . Group I ( n=60 ) , withdraw GnRH agonist continue low dose r-FSH 75 IU . Group II ( n=60 ) , GnRH antagonist administration continue low dose r-FSH 75 IU . When E2＜ 3000 pg/ml , hCG give . Oocyte retrieval perform 36 h hCG administration . The primary outcome measure decrease level estradiol ( E2 ) day coast . The secondary outcome measure number oocytes retrieve , pregnancy rate incidence OHSS . anticipate result : No significant difference see level estradiol ( E2 ) decrease , day coast , number oocyte , pregnancy rate incidence OHSS . GnRH antagonist necessary coasting treatment stop GnRH agonist .</detailed_description>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<criteria>risk ovarian hyperstimulation syndrome allergic GnRH antagonist</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>coast</keyword>
	<keyword>withdraw GnRH agonist</keyword>
	<keyword>GnRH antagonist</keyword>
	<keyword>IVF</keyword>
</DOC>